| Literature DB >> 27619681 |
Tana Machackova1, Hana Mlcochova1, Michal Stanik2, Jan Dolezel2, Michal Fedorko3, Dalibor Pacik3, Alexandr Poprach4, Marek Svoboda1,4, Ondrej Slaby5,6.
Abstract
MicroRNAs (miRNAs) have been proven to be important oncogenes and tumor suppressors in wide range of cancers, including renal cell carcinoma (RCC). In our study, we evaluated miRNA-429 as potential diagnostic/prognostic biomarker in 172 clear cell RCC patients and as a potential regulator of epithelial-mesenchymal transition (EMT) in vitro. We demonstrated that miR-429 is down-regulated in tumor tissue samples (P < 0.0001) and is significantly associated with cancer metastasis (P < 0.0001), shorter disease-free (P = 0.0105), and overall survival (P = 0.0020). In addition, ectopic expression of miR-429 in 786-0 RCC cells followed by TGF-β treatment led to increase in the levels of E-cadherin expression (P < 0.0001) and suppression of cellular migration (P < 0.0001) in comparison to TGF-β-treated controls. Taken together, our findings suggest that miR-429 may serve as promising diagnostic and prognostic biomarker in RCC patients. We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility.Entities:
Keywords: E-cadherin; Epithelial-mesenchymal transition; Renal cell carcinoma; miR-429; microRNA
Mesh：
Substances：
Year: 2016 PMID： 27619681 DOI： 10.1007/s13277-016-5310-9
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283